natgillin/translations-raw huggingface dataset:
The method according to claim 16, wherein the disease is selected from the group consisting of chronic pain, neuropathic pain, postoperative pain, cancer pain, osteoarthritic pain, rheumatoid arthritic pain, neuralgia, fibromyalgia, neuropathies, algesia, nerve injury, migraine, headache, itch, irritable bowel disease, painful bladder syndrome, interstitial cystitis, detrusor overactivity, urinary incontinence, benign prostatic hyperpiesia, lower urinary tract disorders and lower urinary tract symptoms, anxiety, depression and cold-induced/or exhacerbated pulmonary hypertension, chronic obstructive pulmonary disease (COPD) and asthma. 
Spoj za uporabu kao prema zahtjevu 14, naznačen time što je navedena bolest odabrana od kronične boli, neuropatske boli, postoperativne boli, boli zbog raka, osteoartritične boli, reumatoidne artritične boli, neuralgije, fibromialgije, neuropatija, fibromialgije, algezije, ozljede živca, migrene, glavobolje, svrbeža, iritabilne bolesti crijeva, sindroma bolnog mokraćnog mjehura, intersticijskog cistitisa, prekomjerne aktivnosti detruzora, urinarne inkontinencije, neurogene prekomjerne aktivnosti detruzora, idiopatske prekomjerne aktivnosti detruzora, benigne hiperplazije prostate, poremećaja donjeg mokraćnog sustava i simptoma donjeg mokraćnog sustava, anksioznosti, depresije i prehladom izazvane /ili pogoršane plućne hipertenzije, KOPB i astme.
The construct for the use of claim 1, wherein said pediatric acute lymphoblastic leukemia (ALL) is refractory to chemotherapy and allogeneic hematopoietic stem cell transplantation (HSCT). 
Konstrukt namijenjen upotrebi u skladu s patentnim zahtjevom 9 ili 10, naznačen time što se postupak provodi nakon alogenog presađivanja krvotvornih matičnih stanica (HSCT).
is selected from hydrogen, CORa, substituted or unsubstituted C1-C12 alkyl, substituted or unsubstituted C2-C12 alkenyl, and substituted or unsubstituted C2-C12 alkynyl; 
se bira između vodika, CORa, supstituiranog ili nesupstituiranog C1-C12 alkila, supstituiranog ili nesupstituiranog C2-C12 alkenila i supstituiranog ili nesupstituiranog C2-C12 alkinila;
An in vitro method of inhibiting T-cell and/or B-cell proliferation in response to an antigen, comprising administering to the cell a compound represented by the following structural formula: or a pharmaceutically acceptable salt, solvate, or clathrate thereof wherein: X is an optionally substituted phenyl, an optionally substituted triazolyl, an optionally substituted pyridyl, or an optionally substituted indolizinyl; 
In vitro postupak inhibicije proliferacije T-stanice i/ili B-stanice kod odgovora na antigen, naznačen time da se sastoji od davanja stanici spoja predstavljenog sa slijedećom strukturnom formulom: HR P20110180 T1 ili njegove farmaceutski prihvatljive soli, solvata ili klatrata pri čemu: X je opcijski supstituiran fenil, opcijski supstituiran triazolil, opcijski supstituiran piridil, ili opcijski supstituiran indolizinil;
The system according to any of the previous claims, further including a packing station, said packing station providing a multitude of containers for receiving said fish, said multitude of containers are designated different size ranges, said fish is packed in the corresponding container according to the size of said fish, which is derived from said digital representation. 
Sustav (10) prema bilo kojem od prethodnih zahtjeva, naznačen time, da on nadalje obuhvaća položaj za pakiranje, pri čemu je taj položaj za pakiranje opremljen s mnoštvom spremnika za prihvat navedene ribe (22), dok je to mnoštvo spremnika naznačeno prema različitim rasponima veličina, gdje se navedena riba (22) pakira u odgovarajući spremnik prema dimenzijama navedene ribe, koje proizlaze iz spomenutog digitalnog prikazivanja.
The dosage form of the present invention may be a capsule containing the composition, preferably a powdered or granulated solid composition of the invention, within either a hard or soft shell. 
HR P20080686 T3 Dozirni oblik može biti kapsula koja sadrži smjesu, poželjno praškastu ili granuliranu čvrstu smjesu izuma, unutar tvrde ili meke ovojnice.
The method of claim 49, wherein the disorders and diseases are selected from the group consisting of cardiac disorders and diseases, skeletal muscular disorders and diseases, cognitive disorders and diseases, malignant hyperthermia, diabetes, and sudden infant death syndrome. 
Uporaba prema patentnom zahtjevu 10, naznačena time što je poremećaj 1li bolest izabran/izabrana iz grupe koju čine poremećaji i bolesti srca, poremećaji i bolesti skeletnih mišića, kognitivni poremećaji 1 bolesti, maligna hipertermija, dijabetes i sindrom iznenadne smrti novorođenčeta.
A method of inhibiting weight gain or promoting weight loss; lowering circulating LDL levels, and/or increasing HDL/LDL ratio; or treating or reducing obesity, morbid obesity, morbid obesity prior to surgery, obesity linked inflammation, obesity linked gallbladder disease, obesity induced sleep apnea, diabetes, metabolic syndrome, hypertension, atherogenic dyslipidimia, atherosclerois, arteriosclerosis, coronary heart disease, peripheral artery disease, stroke, or microvascular disease in an individual in need thereof comprising administering a compound according to claim 1 . 
(c) liječenje stanja uzrokovanih ili karakteriziranih s viškom tjelesne težine, dok je to liječenje 1/ili prevencija za sljedeće: pretilost, morbidna pretilost, upala povezana s pretilosti, bolest žučnog mjehura povezana s pretilosti, apneja u spavanju uzrokovana s pretilosti, metabolički sindrom, pred-dijabetes, otpornost na inzulin, netolerancija na glukozu, dijabetes tipa II, dijabetes tipa I, hipertenzija, aterogena dislipidemija, ateroskleroza, arterioskleroza, koronarna srčana bolest, bolest periferne arterije, udar ili mikrovaskularna bolest, kod pojedinca kojemu je to potrebno.
The product obtained in the previous stage (mg 280; 0.715 mmol), n-butanol (5 mL) and potassium hydroxide (mg 400; 7.0 mmol) were placed in a double-neck 50 mL anhydrous flask equipped with a reflux condenser with calcium chloride cap and thermometer. 
Produkt dobiven u prethodnom stadiju (mg 280; 0,715 mmol), n-butanol (5 ml) 1 kalij hidroksid (mg 400; 7,0 mmol) stavljeno je u bezvodnu bocu od 50 ml s duplim vratom opremljenom s kondenzatorom za refluks s poklopcem od kalcij klorida i termometrom.
The multispecific antibody of claim 1, wherein the first and second polypeptides further comprise an antibody H chain constant region, and the third and fourth polypeptides comprise an antibody L chain constant region; or 
(a) prvi i drugi polipeptid nadalje obuhvaćaju konstantno područje H-lanca protutijela, a treći i četvrti polipeptid obuhvaćaju konstantno područje L-lanca protutijela; ili (b)
Recombinant expression may be carried out in prokaryotic expression systems like E. coli, or in eukaryotic, and preferably in mammalian, expression systems. 
Rekonbinantna ekspresija može se provesti u prokariotskim ekspresijskim sustavima, poput E. voli, ili u eukariotskim ekspresijskim sustavima, poželjno u ekspresijskim sustavima sisavaca.
The method of claim 7, wherein: the particle contrast agent composition includes: Crystal Violet and New Methylene Blue in amounts sufficient to result in a ratio of the Crystal Violet to the New Methylene Blue between about 1:1 to about 1:500 under staining conditions; and 
Kristal violet i Novo metilensko modrilo u dovoljnoj količini da se dobiju omjer Kristal violet prema Novom metilenskom modrilu između oko 1:1 do oko 1:500 u uvjetima bojenja; i glutaraldehid u dovoljnoj količini da se dobiju koncentracije od ili ispod 0.1% u uvjetima bojenja; i inkubiranje smjese uzorka obuhvaća grijanje smjese uzorka manje od 60 sekundi.
In yet another aspect the hydrogenation of a compound of formula (III) or (IV) is conducted at a pressure of 0.5 to 10 bar, for example 2 to 4 bar. 
Postupak prema zahtjevu 11 naznačen time da se hidrogeniranje spoja formule (II) provodi pri tlaku od 2 do 4 bar.
The compound according to Claim 7, selected from the group consisting of: 
Spoj prema patentnom zahtjevu 12, odabran iz skupine koja sadrži:
The set of polypeptides according to any one of claims 1 to 4 and 7 to 13, wherein any one of said targeting moiety T1 and T2 comprises an allergen or substrate which binds to a clonotypic antibody on the surface of a B cell. 
Skup polipeptida u skladu s bilo kojim od patentnih zahtjeva 1 do 3 i 6 do 12, naznačen time što bilo koji od navedenih ciljajućihih ostataka T1 i T2 sadrži alergen ili supstrat koji se veže na klonotipno protutijelo na površini B-stanice.
Also the above-described powder composition comprising copper sulphate finds advantageous use as an anti-inflammatory and/or antimicrobial agent for the prevention and treatment of foot diseases in ungulates. The powder compositions of the present invention are prepared by mixing powder compounds in the aforedefined weight ratios. 
€) od 0 do 6 težinskih % neorganskog karbonata, i veterinarski prihvatljive adjuvante i/ili inertne punitelje, kao anti-inflamatorno i/ili antimikrobialno sredstvo za uporabu u prevenciji 1 liječenju bolesti stopala kod papkara i kopitara.
The capsule according to any of the preceding claims, wherein the valve means are designed to open the flow path only when the pressure inside the ingredient compartment is higher than ambient pressure. 
Kapsula u skladu s bilo kojim od prethodnih patentnih zahtjeva, naznačena time što ventil (15) je tako osmišljen da omogući protok tek kada tlak u odjeljku (3) bude veći od okolnog tlaka.
A molecule according to claim 9 or 10, wherein the B-aggregating region and the moiety that prevents aggregation are from another protein, or are from the same protein but not immediately adjacent in that protein. 
Molekula prema zahtjevu 9 ili 10, naznačena time da su B-agregacijsko područje i skupina koja sprečava agregaciju iz drugog proteina, ili su iz istog proteina ali nisu u neposrednoj blizini u navedenom proteinu.
The antibody of claim 1 having a heavy chain comprising the amino acid sequence of SEQ ID NO:36 and a light chain comprising the amino acid sequence of SEQ ID NO:38. 
Protutijelo, naznačeno time, da se veže na ljudski CD37 i ima jaki lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:28 i slabi lanac koji sadrži aminokiselinsku sekvencu od SEQ ID NO:30.
a supporting portion, located at the supporting end, that is substantially not deformed and is configured to support the spool from the inside, comprising at least two cylindrical supporting surfaces and, 
a potporni dio koji u biti nije deformiran i služi za podupiranje kalema iznutra, sadržava najmanje dvije cilindrične potporne površine (10) i
The present invention further relates to the nucleic acid previously described which is DNA, cDNA, PNA, CNA, RNA or combinations thereof. The present invention further relates to an expression vector capable of expressing a nucleic acid previously described. The present invention further relates to a peptide as described before, a nucleic acid as described before or an expression vector as described before for use in medicine. 
Nukleinska kiselina, kodirana za peptid za uporabu s bilo kojim od patentnih zahtjeva od 1 do 4, uz uvjet da peptid nije potpuno humani protein, pri čemu je navedena nukleinska kiselina po mogućnosti DNK, cDNK, PNK, RNK ili kombinacija navedenih, ili ekspresijski vektor koji eksprimira navedenu nukleinsku kiselinu. Nukleinska kiselina ili ekspresijski vektor u skladu s patentnim zahtjevom 5 za uporabu u medicini.
USE OF ALS INHIBITOR HERBICIDES FOR CONTROL OF UNWANTED VEGETATION IN ALS INHIBITOR HERBICIDE TOLERANT BETA VULGARIS PLANTS 
Postupak za kontrolu neželjene vegetacije na područjima gdje rastu biljke Beta vulgaris, naznačen time da obuhvaća:
The targeted therapeutic fusion protein of any one of the preceding paragraphs, wherein the spacer comprises a Gly-Ala-Pro (GAP) (SEQ ID NO: 9) or Gly-Pro-Ser (GPS) (SEQ ID NO: 10) amino acid sequence. 
Ciljani terapeutski fuzijski protein prema bilo kojem od prethodnih patentnih zahtjeva, naznačen time da razmaknica sadrži sekvencu aminokiseline Gly-Ala-Pro (GAP) (SEQ ID NO: 9) ili Gly-Pro-Ser (GPS) (SEQ ID NO: 10).
Waterproof formulations allow the user to engage in activities such as swimming while still being protected against ultraviolet radiation. 
Vodootporni pripravci omogućuju korisniku da sudjeluje u aktivnostima kao što je plivanje, a da bude još uvijek zaštićen od ultraljubičastog zračenja.
In another embodiment the invention CNS7056 is provided in a container for pharmaceutical use comprising 10 mg of CNS7056, preferably in a concentration of 1 mg/ml, e.g. a vial, ampoule, syringe or the like. The container comprising 10 mg CNS7056 preferably constitutes a drug product, preferably a ready-to-use drug product. In a further aspect of the invention the pharmacological effect of the ultra short-acting benzodiazepine CNS 7056 and/or the opioid drug can be reversed by another drug, which is referred to as a “reversal agent”. 
CNS 7056 ili njegova sol ili solvat radi primjene sukladno bilo kojem od gornjih zahtjeva, koji je u obliku spremnika za farmaceutsku uporabu koji sadrži 10 mg CNS7056 ili njegove soli ili solvata, a prvenstveno u koncentraciji od 1 mg/ml. CNS 7056 ili njegova sol ili solvat radi primjene sukladno zahtjevu 14, pri čemu spremnik predstavlja farmaceutski proizvod, a prvenstveno farmaceutski proizvod spreman za uporabu. CNS 7056 ili njegova sol ili solvat radi primjene sukladno bilo kojem od gornjih zahtjeva, pri čemu su doze sedativa i/ili analgetika odabrane tako da se ostvari stanje opće anestezije.
A winch according to claim 8 wherein the locking engagement with the feeder arm allows axial movement of the retainer guide against its spring mounting. 
Vitlo prema zahtjevu 7, naznačeno time, da je zahvatno zaključavanje s uvodnom ručicom takvo, da omogućava aksijalno pokretanje zadržne vodilice naspram svoje odskočne montaže.
Purification was performed by crystallization from acetone (30ml) to give the title compound as a white powder (m=6.113g) in a 73% yield. 
Pročišćavanje se izvrši prekristalizacijom iz acetona (30 mL) da se dobije spoj iz naslova u obliku bijelog praha (m=6,113 g) s prinosom od 73 %.
a secondary magnetic separator. The plant according to claim 12, wherein the shredding means are adapted to perform shredding down to a screen passage size Dmax not exceeding 50 mm, preferably between 20 and 30 mm. 
Postrojenje sukladno patentnom zahtjevu 10, naznačeno time da je jedinica za usitnjavanje prilagođena izvesti usitnjavanje sve do prolaska kroz mrežicu do veličine presjeka maksimalno manje od 50 mm, poželjno između 20 1 30 mm.
the targeter-RNA, or a nucleic acid encoding the targeter-RNA; and 
polipeptid Cas9, ili polinukleotid koji kodira navedeni polipeptid Cas9; i
The CHO cell of claim 4, wherein said deleted sequence comprises a portion of the telomeric region of chromosome 8 of a CHO cell. 
Stanica CHO u skladu s patentnim zahtjevom 3, naznačena time što navedeni deletirani slijed sadrži dio telomernog područja kromosoma 8 stanice CHO.
The method of claim 1, the prodrug compound is represented by a structure of Formula 4 or stereoisomer thereof or pharmaceutically acceptable salt thereof 
Aa Å IERNNIA 1, tvar sadrži strukturu Formule 4 ili njen stereoizomer ili njenu farmaceutski soi Å ta Pa" pu gos
A therapeutic method for the treatment of pain comprising the administration by a parenteral or mucosal route of the analgesic composition of claim 1 comprising buprenorphine and naltrexone, wherein the buprenorphine and naltrexone are used in an amount such that the medicament is delivered to a patient, or reaches in the plasma of a patient, at a ratio by weight in the range: 100:1 to 500:1, buprenorphine:naltrexone. 
Uporaba buprenorfina i naltreksona u proizvodnji lijeka za liječenje boli, gdje se buprenorfin i naltrekson koriste u količini takvoj da se lijek doprema bolesniku, ili dolazi do plazme bolesnika, u težinskom omjeru u rasponu od 100:1 do 5000:1 buprenorfin prema naltreksonu.
at least 95% of the lipoprotein complexes are in the form of particles of 4 nm to 15 nm in size as measured by dynamic light scattering (“DLS”); at least 95% by weight of ApoA-I in said population is in mature form; no more than 5% by weight of ApoA-I in said population is in immature form; and 
najmanje 80%, najmanje 85%, najmanje 90%, najmanje 95% lipoproteinskih kompleksa su u obliku čestica veličine od 4 nm do 15 nm, veličine od 6 nm do 15 nm, veličine od 4 nm do 12 nm, veličine od 6 nm do 12 nm, ili veličine od 8 nm do 12 mjereno gel permeacijskoom kromatografijom ("GPC") ili dinamičkim raspršenjem svjetlosti ("DLS");
Affinity Selection on Purified Protein Targets. 
HR P20110369 T1 Odabir na stanice MCF-7
after it has been converted to pixels compressing said encrypted character string, thereby creating a scrambled image, and transmitting said scrambled image, 
(6) nakon što se spomenuti šifrirani niz znakova pretvori u piksele koji ga zbijaju, a time se stvara ispremetana slika, 1
The process of claim 1, wherein the compound of Formula III, or a salt thereof, is prepared by contacting a compound of Formula IV: or a salt thereof, wherein Y is bromo or chloro, with a piperazine compound having the structure: or a salt thereof, wherein Lv is a leaving group and R1 is an amino protecting group. 
ili njegove soli, gdje Y je brom ili klor, sa spojem piperazina koji ima sljedeću strukturu: ili s njegovom soli, pri čemu je Lv izlazna skupina i R1 je amino zaštitna skupina.
The pallet container of claim 1, wherein the fire-protection insulation mat includes a blank panel provided for a base face of the internal container and having four lateral edges, each said lateral edge including an overlapping strip, with two opposite narrow ones of the overlapping strips on longer ones of the lateral edges of the internal container having an equal width of approx. 50 mm to 125 mm. 
Paletni spremnik prema patentnom zahtjevu 1, naznačen time što unutarnji spremnik od plastičnog materijala ima dva dulja i dva kraća bočna ruba, pri čemu je svaka prazna ploča za stranu osnovice unutarnjeg spremnika od plastičnog materijala na sva četiri bočna ruba opremljena s jednom preklopnom trakom, pri čemu samo dvije suprotne uske preklopne trake na duljim bočnim rubovima unutrašnjeg spremnika imaju jednaku širinu od približno 50 mm do 125 mm, poželjno od približno 75 mm.
Tea (35 mL) followed by DMAP (1.284 g) and TES-CI (˜30 mL, 3.5 eq) were added to the solution and stirred. 
Bili su dodani TEA (35 mL) i nakon toga DMAP (1.284 g) i TES-CI (330 mL, 3.5 ekv.) u otopinu i promiješam.
wherein said VEGF binding immunoglobulin single variable domain has the following CDR sequences: 
navedena jednostruka varijabilna domena imunoglobulina koja se veže na VEGF, ima sljedeće CDR-sekvence:
The operator can position himself so as to have the best possible view of the dock, or of the anchor, but can still control the boat as if the were located at the control station. 
Operater se može postaviti tako da ima najbolji mogući pogled na pristajalište, ili na sidru, ali istovremeno može upravljati plovilom kao da se nalazi na upravljačkom mjestu.
Such top coatings are widely used in the art for applications where an electrical conductivity is not required. 
Takvi se gornji slojevi naširoko koriste u tehnici za primjene u kojima se ne traži električna vodljivost.
has the meanings indicated for the compound of formula I, and/or converting a base or acid compound of formula I into one of its salts. 
R* ima značenje navedeno u zahtjevu 1, i/ili baza ili kiselina formule I se pretvara u jednu od njegovih soli.
The composition of statement 2, wherein the zeta potential of the particle is from about -50 mV to about -40 mV. 
Spoj sukladno zahtjevu 1, pri čemu je zeta potencijal čestice od oko -50 mV do oko -40 mv.
The composition for use according to claim 13, wherein the endogenous 11 -cis- retinal deficiency is associated with Age-Related Macular Degeneration, Leber Congenital Amaurosis (LCA), Retinitis Punctata Albesciens, Congenital Stationary Night Blindness, Fundus Albipunctatus, loss of night vision, contrast sensitivity or Retinitis Pigmentosa. 
Upotreba iz patentnog zahtjeva 17 ili 18, naznačena time, da je deficijencija endogenog 11-cis-retinala povezana sa senilnom makularnom degeneracijom, Leberovom kongenitalnim amaurozom (LCA), retinitis punctata albesciens, kongenitalnim stacionarnim noćnim sljepilom ili fundus albipunctatus.
In a further variant the method may comprise at least one of the steps of: receiving a data request from the client, said data request comprising a session key; decrypting the private key stored in the memory using the session key; and/or decrypting the scrambling key stored in the personal data storage unit using the private key. 
Postupak u skladu s bilo kojim od patentnih zahtjeva 1-5, naznačen time što postupak dodatno uključuje korak: primanja zahtjeva za transakcijom od strane klijenta, gdje navedeni zahtjev za transakcijom sadrži sesijski ključ; dešifriranja osobnog ključa spremljenog u memoriji uz upotrebu sesijskog ključa; dešifriranja ključa za premetanje spremljen u jedinici za spremanje osobnih podataka uz upotrebu osobnog ključa.
A cancer chemotherapeutic agent according to (6) above, wherein the drug containing a cholestanol derivative is a liposomal formulation. 
Protutumorsko kemoterapijsko sredstvo u skladu s patentnim zahtjevom 5, naznačen time, da je lijek koji sadrži derivat kolestanola liposomska formulacija.
is a cross-section through a profile. 
je poprečni presjek kroz profil.
figure 4 is a view of the rear end of the system; figure 5 is a section according to line V-V in figure 4. 
prikazuje pogled sa stražnjeg kraja na ovaj sustav; slika 5 = prikazuje presjek koji je u skladu s linijom V-V iz slike 4.
The best ratio is influenced by copper source used, co-biocides, and other additives. 
Na najbolji omjer se utječe izborom upotrijebljenog izvora bakra, ko-biocida, i drugih aditiva.
The monoclonal antibody or the antigen-binding portion according to claim 7, wherein said inflammatory disease is selected from the group consisting of vasculitis, arthritis, sepsis, septic shock, endotoxic shock, toxic shock syndrome, acquired respiratory distress syndrome, glomerulonephritis, inflammatory bowel disease, Crohn's disease, ulcerative colitis, peritonitis, nephritis and psoriasis. 
Monoklonalno protutijelo ili njegov dio koji se veže na antigen prema zahtjevu 7, naznačen/o time, da je spomenuta upalna bolest odabrana iz skupine koju čine vaskulitis, artritis, sepsa, septički šok, endotoksički šok, sindrom toksičkog šoka, sindrom stečenog respiratornog poremećaja, glomerulonefritis, upalna bolest crijeva, Chronova bolest, ulcerativni kolitis, peritonitis, nefritis i psorijaza.
A compound, which is: or a pharmaceutically acceptable salt, solvate, or stereoisomer thereof. 
[image] ili njegova farmaceutski prihvatljiva sol, solvat ili stereoizomer.
The combination for use according to claim 11 wherein the disease is congestive heart failure. 
Spoj, namijenjen upotrebi u skladu s patentnim zahtjevom 12, naznačen time što je bolest kongestivna srčana insuficijencija.
The thermoplastic film according to claim 2, wherein the ratio of the average width to the average length of said elements of the current invention is in the range of 1:50-1:500,000. 
Termoplastična folija sukladno zahtjevu 1, pri čemu omjer prosječne širine u odnosu na prosječnu duljinu elemenata navedenog izuma iznosi 1:500-1:10,000,000, poželjno opsega 1:50-1:500,000.
The method as in item 1 or 2, wherein the carrier is a wood based board, preferably a HDF or MDF board. 
Postupak prema zahtjevu 1 ili 2, naznačen time da je nosač (4) ploča temeljena na drvu, poželjno HDF ploča ili MDF ploča.
In this respect, EP 0 963 379 and US 6,423,358 disclose examples of fibre containing sugar substitutes on a 1/1 volume basis. 
U tom smislu, u EP 0 963 379 1 US 6,423,358 otkrivaju se primjeri vlakana koja sadržavaju nadomjestke za šećer u volumnim omjerima 1/1.